Ipatasertib is currently being studied in combination with different agents, such as darolutamide and ADT, in the neoadjuvant setting in high risk, prostate cancer with PTEN-loss (NCT04737109) and in the metastatic setting in combination with atezolizumab and docetaxel (NCT04404140), or rucaparib in a phase I study (NCT03840200). This evidence concerns the gene PTEN and prostate cancer.